<DOC>
	<DOCNO>NCT00428545</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose Avastin™ ( bevacizumab ) Velcade™ ( bortezomib ) give combination patient metastatic unresectable advanced malignancy . The safety effectiveness drug combination also study .</brief_summary>
	<brief_title>Bevacizumab Bortezomib Patients With Advanced Malignancy</brief_title>
	<detailed_description>Bevacizumab anti-cancer drug design prevent slow growth cancer cell block blood vessel supply nutrient necessary tumor growth . Bortezomib anti-cancer drug design block protein need tumor growth . This may cause cancer cell die . If find eligible take part study , enrol group 6 participant . The first group participant receive low dose bevacizumab bortezomib combine . The next group participant receive next high dose bevacizumab bortezomib combine . This process continue study doctor find high dose tolerate . The dose receive depend enrol study safety data available time . The dose bevacizumab bortezomib receive may lower tolerate study drug combination well . You receive dos study drug high dose first assign . Bevacizumab bortezomib give `` cycle . '' Cycles 21 day long longer , depend side effect may experience . During Cycle 1 , Day 1 , receive bevacizumab vein 90 minute . If bevacizumab well tolerated Cycle 1 , give 60 minute Cycle 2 . If well tolerate Cycle 2 , give 30 minute Cycle 3 . It continue give 30 minute cycle long drug still well tolerate . Depending dose level assign , receive bortezomib Days 1 8 , Days 1 , 4 , 8 , 11 . You receive bortezomib vein 1-5 minute . You blood draw ( 1 tablespoon time ) routine test week Cycle 1 . You physical exam sometime Days 7 14 Cycle 1 . During rest cycle , physical exam blood drawn ( 1 tablespoon time ) routine test every 3 week . The status disease measure CT MRI scan every 2 cycle . Once high tolerable dose ( maximum tolerate dose MTD ) combination bevacizumab bortezomib find , 15 additional participant advance cancer enrol receive dose , researcher learn effect study drug tumor . A tumor biopsy require within two week first treatment end first cycle patient . Up 10 additional patient kidney cancer enrol receive high tolerable dose . Tumor biopsies optional patient kidney cancer . You may continue receive bevacizumab bortezomib study , unless cancer get bad experience intolerable side effect . Once participation study , receive standard care follow-up disease . This investigational study . Bevacizumab bortezomib FDA approve commercially available . Bevacizumab FDA approve treatment colorectal cancer . Bortezomib FDA approve treatment multiple myeloma . The combination use bevacizumab bortezomib investigational authorize use research . Up 111 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients advance metastatic cancer refractory standard therapy , relapse standard therapy , standard therapy induces complete response ( CR ) rate least 10 % improve survival least three month . 2 . Patients must &gt; /= 6 week beyond treatment nitrosoureas mitomycinC , &gt; /= 4 week beyond chemo radiotherapy , must recover &lt; /= grade 1 toxicity treatmentlimiting toxicity prior therapy . ( Exception : patient receive palliative low dose radiotherapy limbs 14 week therapy provide pelvis , rib , sternum , scapula , vertebra skull include radiotherapy field ) . Patients receive nonchemotherapeutic biologic agent must wait 5 halflives 4 week , whichever short , last day treatment . 3 . The Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; /= 2 ( Karnofsky &gt; /= 60 % ) . 4 . Patients must normal organ marrow function define : leukocyte &gt; /= 3,000/mL ; absolute neutrophil count &gt; /= 1,500/mL ; platelet &gt; /=75,000/mL ; creatinine &lt; /= 2 * Upper Limits Normal ( ULN ) ; total bilirubin &lt; /= 2.0 ; alanine aminotransferase ( ALT SGPT ) &lt; /= 3 * ULN ; Exception patient liver metastasis : total bilirubin &lt; /= 3 * ULN ; ALT ( SGPT ) &lt; /= 5 * ULN . 5 . The effect bevacizumab develop human fetus unknown . Angiogenesis critical importance fetal development , bevacizumab likely adverse consequence term fetal development . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry , duration study participation , 30 day last dose . 6 . Ability understand willingness sign write informed consent document . 7 . Life expectancy least 3 month . 1 . Patients hemoptysis within 28 day prior enter study . 2 . Patients clinically significant unexplained bleeding within 28 day prior enter study . 3 . Uncontrolled systemic vascular hypertension . 4 . Patients clinically significant cardiovascular disease , include : history cerebrovascular accident ( CVA ) within 6 month , myocardial infarction unstable angina within 6 month , unstable angina pectoris . 5 . Uncontrolled intercurrent illness include , limited , ongoing active infection require parenteral antibiotic Day 1 . 6 . Pregnant lactating woman . 7 . History hypersensitivity bevacizumab , murine product , component formulation . 8 . History hypersensitivity bortezomib , boron , mannitol , component formulation . 9 . ( Only 10patient expansion cohort identification MTD ) : Patients must willing undergo biopsy treatment end cycle 1 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Advanced Malignancy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Myeloma</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Avastin</keyword>
	<keyword>Anti-VEGF monoclonal antibody</keyword>
	<keyword>rhuMAb-VEGF</keyword>
	<keyword>Bortezomib</keyword>
	<keyword>Velcade</keyword>
	<keyword>PS-341</keyword>
	<keyword>LDP-341</keyword>
	<keyword>MLN341</keyword>
</DOC>